Biophytis SA

( )
BPTS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ICLRICON plc -0.61%230.422.8%$104.93m
ARGXargenx SE 2.04%374.030.0%$97.17m
VRXValeant Pharmaceuticals International, Inc. -11.39%5.1814.1%$30.48m
RVMDRevolution Medicines, Inc. -2.62%23.760.0%$26.94m
ENVBEnveric Biosciences, Inc. -11.19%6.190.0%$22.45m
USNAUSANA Health Sciences, Inc. -3.78%67.124.2%$4.50m
CLVRClever Leaves Holdings, Inc. -8.30%0.990.0%$2.12m
ANIKAnika Therapeutics, Inc. -3.84%22.569.8%$1.55m
BGXXBright Green Corp. -4.10%1.170.0%$0.98m
PMCBPharmaCyte Biotech, Inc. -0.78%2.560.0%$0.63m
CDTXCidara Therapeutics, Inc. -6.70%0.630.7%$0.54m
CDXCChromadex Corp. -3.52%1.922.7%$0.49m
FLGCFlora Growth Corp. -8.38%0.700.0%$0.40m
IBIOiBio, Inc. -8.85%0.250.2%$0.39m
NATRNature's Sunshine Products, Inc. -3.67%10.500.4%$0.37m

Company Profile

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.